- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Amino groups.
Displaying page 1 of 2.
EudraCT Number: 2007-001378-97 | Sponsor Protocol Number: Ped3CB/P01/06/Mu.B | Start Date*: 2007-08-14 | |||||||||||
Sponsor Name:Baxter SAS | |||||||||||||
Full Title: Safety during use of paediatric triple chamber bag formulas administered IV at a weight dependant dose during 5 consecutive days in paediatric patients up to 18 years requiring parenteral nutrition... | |||||||||||||
Medical condition: The study is not focussed on a particular pathology but rather on the use of triple chamber bags in paediatrics, in any pathology requiring parenteral nutrition | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002243-25 | Sponsor Protocol Number: CAAE581A2203E2 | Start Date*: 2007-08-28 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis | ||
Medical condition: Osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002466-20 | Sponsor Protocol Number: 4087 | Start Date*: 2012-08-16 | |||||||||||
Sponsor Name:Royal Liverpool And Broadgreen University Hospitals NHS Trust | |||||||||||||
Full Title: An exploratory, randomised, 3-way crossover study to determine the effect of paracetamol on urinary cystine excretion in cystinuria | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012602-39 | Sponsor Protocol Number: 05-NEOV-002 | Start Date*: 2010-05-17 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact(R) in premature very low bir... | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for premature ... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007932-25 | Sponsor Protocol Number: 28091 | Start Date*: 2008-05-07 |
Sponsor Name:Merck Lipha Santé | ||
Full Title: A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) ... | ||
Medical condition: Prevention of premature ovulation in polycystic ovarian women undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000576-33 | Sponsor Protocol Number: RBN 542 | Start Date*: 2006-06-13 |
Sponsor Name:St Helens & Knowsley Hospitals NHS Trust [...] | ||
Full Title: Pilot Study to investigate the role of Glutamine in the early protective stress response | ||
Medical condition: Critical Illness | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000429-20 | Sponsor Protocol Number: 05-NEOV-001 | Start Date*: 2008-10-17 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions. | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm an... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018024-15 | Sponsor Protocol Number: CUV100 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:Clinuvel Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Mild to Moderate Acne... | |||||||||||||
Medical condition: Acne vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001441-39 | Sponsor Protocol Number: VIR20001 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) | |||||||||||||
Medical condition: COVID-19, acute respiratory illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000096-16 | Sponsor Protocol Number: INCB 08721-204 | Start Date*: 2006-03-30 |
Sponsor Name:Incyte Corporation | ||
Full Title: A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimize... | ||
Medical condition: HIV-1 | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012603-26 | Sponsor Protocol Number: 05-NEOV-003 | Start Date*: 2010-04-08 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH [...] | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature ... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003571-12 | Sponsor Protocol Number: GLU0409 | Start Date*: 2006-11-15 |
Sponsor Name:Barts and the London NHS Trust | ||
Full Title: Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition. | ||
Medical condition: 60 consecutive critically ill patients will be recruited with illnesses such as severe infection, trauma and post-surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002472-16 | Sponsor Protocol Number: CCD09 | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:Cytonet GmbH & Co KG | |||||||||||||
Full Title: Open, prospective, diagnostic, multicentre study in healthy subjects, patients with urea cycle disorders (UCD), and carriers of UCD mutations, to evaluate in vivo ureagenesis measured after a singl... | |||||||||||||
Medical condition: 1. Healthy subjects 2. Symptomatic UCD patients with genetically confirmed CPSD, OTCD, ASSD, or ASLD 3. Asymptomatic carriers of UCD mutations (e.g. parents) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002695-34 | Sponsor Protocol Number: CS-201 | Start Date*: 2009-01-23 | |||||||||||
Sponsor Name:Kringle Pharma Europe AB | |||||||||||||
Full Title: A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of ChronSeal® (5-amino-acid deleted recombinant human Hepatocyte Gr... | |||||||||||||
Medical condition: Non-malignant full skin chronic venous leg ulcers of an area 3 - 20 cm2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000148-23 | Sponsor Protocol Number: FAPI-PET-Trial | Start Date*: 2021-06-30 |
Sponsor Name:University Hospital Essen | ||
Full Title: 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial | ||
Medical condition: Patients receiving 68Ga-FAPI-46 PET both at initial diagnosis and restaging before treatment decisions | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004442-16 | Sponsor Protocol Number: cro524 | Start Date*: 2006-11-29 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Modulation of lung injury complicating lung resection | |||||||||||||
Medical condition: Acute respiratory distress syndrome, Acute Lung Injury, Ventilator-Induced Lung Injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018168-81 | Sponsor Protocol Number: EMR-700773-503 | Start Date*: 2010-04-16 | |||||||||||
Sponsor Name:Merck Serono Norway | |||||||||||||
Full Title: ENDURE: A Phase IV, prospective, open-label, uncontrolled, multi-centre cohort trial to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 28... | |||||||||||||
Medical condition: Subjects diagnosed with Phenylketonuria (PKU) (classic or mild PKU, or mild hyperphenylalaninaemia (HPA)). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001709-27 | Sponsor Protocol Number: 26866138MMY2038 | Start Date*: 2006-09-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® when added to Adriamycin-Dexamethasone Treatment versus Vincristine-Adriamycin-D... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001842-34 | Sponsor Protocol Number: DOXIL-MMY-3001 | Start Date*: 2004-11-29 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | ||
Medical condition: Recurred or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004262-34 | Sponsor Protocol Number: GRASPANC2013-03 | Start Date*: 2014-02-24 | |||||||||||
Sponsor Name:ERYTECH Pharma | |||||||||||||
Full Title: Phase II, randomized, controlled, clinical trial exploring efficacy and safety of ERY001 (L-asparaginase encapsulated in Red Blood Cells) in association with gemcitabine or FOLFOX4 in second-line t... | |||||||||||||
Medical condition: Pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
